Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· June 29, 2026

PROSPERITY BANCSHARES, INC.® INVITES YOU TO JOIN ITS SECOND QUARTER 2026 EARNINGS CONFERENCE CALL

View original at finance.yahoo.com
PROSPERITY BANCSHARES, INC.® INVITES YOU TO JOIN ITS SECOND QUARTER 2026 EARNINGS CONFERENCE CALL HOUSTON, June 29, 2026 /PRNewswire/ -- In conjunction with Prosperity Bancshares, Inc.® (NYSE: PB) Second Quarter 2026 Earnings Announcement, scheduled before the market opens on Wednesday, July 29, 2026, you are invited t…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Prosperity Bancshares was founded in 1983 and operates on a community banking philosophy

    60% confidence

  • Prosperity currently operates 311 full-service banking locations across Texas and Oklahoma

    60% confidence

  • Forward-looking statements are subject to risks including credit quality deterioration, competitor actions, regulatory changes, acquisition integration challenges, and macroeconomic factors such as interest rate and commodity price fluctuations

    60% confidence

  • As of March 31, 2026, Prosperity Bancshares is a $43.619 billion Houston, Texas-based regional financial holding company

    60% confidence

  • Prosperity offers digital banking solutions, credit and debit cards, mortgage services, treasury management solutions, and wealth management services including trust and retail brokerage in addition to traditional deposit and loan products

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com